WhiteSands Alcohol & Drug Rehab Lakeland has published a new in-depth educational resource on its website examining the medical and behavioral risks associated with mixing Eliquis, a commonly ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

Eliquis and Xarelto, two blood-thinning medications that are already among Medicare's costliest, have seen their list prices more than double since entering the market, finds a new report by Patients ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor ...

Choice of direct oral anticoagulant (DOAC) mattered for clinical outcomes among adults with atrial fibrillation (Afib), a study based on U.S. insurance claims found. Apixaban (Eliquis) users had ...

NEW ORLEANS — New data from the AUGUSTUS trial provide insight on the appropriate antithrombotic regimen after ACS or PCI in patients with atrial fibrillation. Perspectives from Arnold Seto, MD, MPA; ...

The popular diabetes treatment Jardiance and the blood thinner Eliquis are among the first drugs that will be targeted for price negotiations in effort to cut Medicare costs. President Joe Biden's ...

Patients with active cancer who developed a blood clot, or venous thromboembolism (VTE), and were treated with blood-thinning medication for at least six months, followed by an additional 12 months of ...

TAIPEI, Oct. 1, 2025 /PRNewswire/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...

Eliquis had a market value of $14 billion during the 12 months ended May 2021, according to industry data. The Food and Drug Administration has cleared Breckenridge’s apixaban tablets. The medication ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the action ...